A Randomized, Multi-regional, Double-blind, Double-dummy Parallel-group, Placebo and Allopurinol-controlled Phase 3 Study to Assess the Efficacy and Safety of Tigulixostat in Gout Patients With Hyperuricemia
ClinicalTrials.gov processed this data on October 17, 2023. Link to the current ClinicalTrials.gov record.Recruitment Status
RECRUITING (See Contacts and Locations)Verified October 2023 by LG Chem
Sponsor
LG ChemInformation Provided by (Responsible Party)
LG ChemClinicaltrials.gov Identifier
NCT05586971Other Study ID Numbers: LG-GDCL010
First Submitted: October 16, 2022
First Posted: October 19, 2022
Last Update Posted: October 18, 2023
Last Verified: October 2023
History of Changes
Listing a study on this site does not mean it has been evaluated by the U.S. Federal Government. The safety and scientific validity of a study listed on ClinicalTrials.gov is the responsibility of the study sponsor and investigators. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating.
ClinicalTrials.gov, a resource provided by the U.S. National Library of Medicine (NLM), is a registry and results information database of clinical research studies sponsored or funded by a broad range of public and private organizations around the world. Not all studies listed on ClinicalTrials.gov are funded by the National Institutes of Health (NIH) or other agencies of the U.S. Federal Government. Not all listed studies are regulated and/or reviewed by the U.S. Food and Drug Administration or other governmental entities.
Information on ClinicalTrials.gov is provided by study sponsors and investigators, and they are responsible for ensuring that the studies follow all applicable laws and regulations. NLM staff do not verify the scientific validity or relevance of the submitted information beyond a limited quality control review for apparent errors, deficiencies, or inconsistencies.
Choosing to participate in a study is an important personal decision. Before you participate in a study, discuss all options with your health care provider and other trusted advisors. For more information about participating in clinical studies, see Learn About Clinical Studies, which includes questions that you might want to ask before deciding to participate in a study.
For more information about using the information on ClinicalTrials.gov, please also see Terms and Conditions.
See also the Web Policies and Notices for the NIH web site.
Study Description
Not ProvidedCondition or Disease | Intervention/Treatment |
---|---|
|
|
Study Design
Study Type | Interventional |
---|---|
Anticipated Enrollment | 2542 participants |
Design Allocation | Randomized |
Interventional Model | Parallel Assignment |
Masking | Quadruple |
Primary Purpose | Treatment |
Official Title | A Randomized, Multi-regional, Double-blind, Double-dummy Parallel-group, Placebo and Allopurinol-controlled Phase 3 Study to Assess the Efficacy and Safety of Tigulixostat in Gout Patients With Hyperuricemia |
Study Start Date | March 30, 2023 |
Anticipated Primary Completion Date | July 2025 |
Anticipated Study Completion Date | December 2025 |
Groups and Cohorts
Group/ Cohort | Intervention/ Treatment |
---|---|
|
|
|
|
|
|
|
|
|
|
Outcome Measures
Primary Outcome Measures
- The proportion of subjects with sUA levels <6.0 mg/dL sustained at months 4, 5, and 6 [Up to Month 6] Serum uric acid (sUA) level will be measured at Month 4,5, and 6
Secondary Outcome Measures
- The proportion of subjects with sUA levels <5.0 mg/dL sustained at months 4, 5, and 6 [Up to Month 6] Serum uric acid (sUA) level will be measured at Month 4,5, and 6
- Proportion of subjects with at least one gout flare from Month 6 to Month 12. [From Month 6 to Month 12] Gout flare (intense pain, swelling, or/and tenderness in the joint area) will be assessed from baseline up to 12 months
- Proportion of subjects with complete resolution of ≥1 target tophus by Month 12 [Up to Month 12] Tophi will be measured by independent central blind reader
- Incidence rate of adverse event [Up to Month 12] Safety assessment
Eligibility Criteria
Ages Eligible for Study | 18 Years to 85 Years (Adult, Older Adult) |
---|---|
Sexes Eligible for Study | All |
Accepts Healthy Volunteers | No |
Inclusion Criteria |
|
Exclusion Criteria |
|
Contacts and Locations
Sponsors and Collaborators | LG Chem |
---|---|
Locations |
|
Investigators |
More Information
Additional Relevant MeSH Terms
- Gout
- Hyperuricemia
- Arthritis
- Joint Diseases
- Musculoskeletal Diseases
- Crystal Arthropathies
- Rheumatic Diseases
- Purine-Pyrimidine Metabolism, Inborn Errors
- Metabolism, Inborn Errors
- Genetic Diseases, Inborn
- Metabolic Diseases
- Pathologic Processes